This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D80.8 | Synonyms: Other antibody deficiency immunodeficiency, Good syndrome, Thymoma with immunodeficiency
The ICD-10 code D80.8 is a comprehensive category that includes other immunodeficiency disorders mainly characterized by antibody deficiency but not classified into the other previously named specific categories (D80.0~D80.6). The most clinically important representative disease is thymoma-associated immunodeficiency (Good syndrome).
Good syndrome (the combination of thymoma and immunodeficiency) became known when Robert Good in 1954 first described hypogammaglobulinemia and recurrent infections in a patient with thymoma. Over the following decades, it was confirmed that this syndrome occurs in about 10% of patients with thymoma.
In the International Union of Immunological Societies (IUIS) classification of primary immunodeficiencies, D80.8 includes disorders mainly characterized by antibody deficiency that do not fit a specific classification. In the 2019 IUIS update as well, thymoma-associated immunodeficiency, unclassified hypogammaglobulinemia and others are included in this category.
In Korea, cases are reported in which Good syndrome is diagnosed during immune evaluation after detection of a thymoma. It mostly occurs in adults aged 40~70, and immunodeficiency often persists even after thymoma resection.
Impaired T cell development and suppression of B cell function by the thymoma are the core mechanisms. Tumor cells of the thymoma are known to impair normal T cell development and suppress the generation and function of mature B cells and plasma cells. Why immunodeficiency persists even after thymoma resection has not yet been fully elucidated.
Cases with prominent antibody deficiency that do not fully meet the CVID diagnostic criteria (low IgG, IgA, IgM, presence of B cells, poor antibody response) may be classified under D80.8. Various molecular causes are under study.
Immunosuppressants (rituximab, corticosteroids, chemotherapy), malignant lymphoma, chronic lymphocytic leukemia (CLL), multiple myeloma, organ transplantation and others can cause secondary antibody deficiency. Cases with a secondary cause should strictly be excluded from the primary category of D80.8.
Good syndrome occurs sporadically, and no association with specific genetic variants has been established. Thymoma itself may rarely be associated with genetic predisposition (MEN1, chromosome 14 abnormalities, etc.), but genetic factors in the development of the immunodeficiency are unclear.
In some patients with unclassified antibody deficiency, genetic variants similar to those in CVID (TNFRSF13B, TNFRSF13C, CARD11, PIK3CD, PIK3R1, etc.) are found. With advances in next-generation sequencing (NGS), genetic diagnosis is becoming possible in some cases whose cause was previously unknown.
Most disorders classified under D80.8 occur sporadically. Familial occurrence is rare among unclassified hypogammaglobulinemias, and when it occurs, gene panel testing is recommended.
Good syndrome is estimated to occur in about 6~11% of patients with thymoma. The prevalence of thymoma itself is very low, at about 1.5 per million population, and Good syndrome is an even rarer disease.
Good syndrome mainly occurs in adults aged 40~70. As with thymoma, the male-to-female ratio is nearly equal. It is very rare in children.
With advances in diagnostic technology, many patients previously classified under D80.8 are gradually receiving specific molecular diagnoses, so the number of patients remaining under this code is decreasing.
In Korea, Good syndrome is reported sporadically at institutions specializing in thymoma treatment (Samsung Medical Center, Asan Medical Center, etc.). Published data on accurate national statistics for patients registered under code D80.8 are lacking.
In thymoma, normal positive and negative selection of T cells occurs abnormally, damaging the mature T cell pool. B cell reduction, plasma cell deficiency and hypogammaglobulinemia accompany it. Autoimmune phenomena may also arise from regulatory T cell (Treg) abnormalities.
In patients with thymoma, the number of peripheral B cells may be markedly reduced or almost absent. This is presumed to be because abnormal T cells produced in the thymoma suppress B cell development and function.
Defects in functional antibody responses lead to susceptibility to bacterial infections. T cell-dependent antibody responses are also reduced because of decreased CD4+ T cells. In addition, defects in cellular immunity increase the risk of opportunistic infections.
Recurrent bacterial infections (pneumonia, sinusitis, bronchitis) are the most common initial symptoms. Patients often present with recurrent infections before or after detection of the thymoma. Chronic diarrhea, weight loss and chronic cough may also occur.
Pneumocystis jirovecii pneumonia, CMV infection and herpesvirus infections can occur. Chronic mucocutaneous candidiasis has also been reported. This is because a T cell function defect accompanies it.
Autoimmune diseases frequently accompany Good syndrome. Pure red cell aplasia (PRCA), myasthenia gravis, lichen planus, Graves disease, hemolytic anemia and others may accompany thymoma.
Symptoms caused by the thymoma itself may include chest pain, cough and superior vena cava syndrome. It is also often asymptomatic and found incidentally on imaging.
Abnormal lung auscultation findings due to recurrent pneumonia, and clubbing in bronchiectasis, may be observed. With associated pure red cell aplasia, pallor due to anemia appears. With associated myasthenia gravis, muscle weakness, ptosis, diplopia, etc. are found.
Marked reduction of all of IgG, IgA and IgM (panhypogammaglobulinemia) is typical. B cells are often nearly undetectable.
On flow cytometry, peripheral blood B cells (CD19+) are markedly reduced or absent. Decreased CD4+ T cells and an inverted CD4/CD8 ratio may be observed. NK cell counts may also be decreased.
On chest CT, an anterior mediastinal mass is the characteristic finding of thymoma. Lung CT may reveal bronchiectasis and infiltrates due to pulmonary infection.
In all patients diagnosed with thymoma, quantification of serum immunoglobulins (IgG, IgA, IgM) and peripheral blood B cell counts are performed. Immune function evaluation is recommended both before and after thymoma resection.
In adults with recurrent opportunistic infections, recurrent pneumonia or chronic diarrhea, serum immunoglobulins and B cell counts are tested, and chest CT is used to evaluate for thymoma.
Immunodeficiency screening is also recommended in patients with thymoma-associated autoimmune diseases such as pure red cell aplasia, myasthenia gravis and Graves disease.
① Histologically confirmed thymoma ② Panhypogammaglobulinemia (marked reduction of IgG, IgA, IgM) ③ Reduced or absent B cells (flow cytometry)
Differential diagnoses include ① CVID (no thymoma) ② XLA (male, absent B cells) ③ SCID ④ secondary immunodeficiency due to HIV infection ⑤ drug-induced hypogammaglobulinemia such as from rituximab.
The WHO classification (types A~C, thymic carcinoma) of the thymoma is determined by chest CT-guided biopsy or pathological examination after surgical resection. Thymoma type is associated with prognosis.
The degree of functional antibody deficiency is evaluated by testing specific antibody responses after vaccination (PPSV23, protein conjugate vaccines).
The definitive treatment of thymoma is surgical resection (thymectomy). Postoperative radiotherapy and chemotherapy are added according to thymoma stage.
IVIG (intravenous immunoglobulin, 400~600 mg/kg/3~4 weeks) or SCIG is given to maintain serum IgG trough levels at 700~900 mg/dL or above. Because immunodeficiency persists even after thymoma resection, long-term immunoglobulin replacement therapy is needed.
PCP prophylaxis with TMP-SMX and prevention of bacterial infections with azithromycin or amoxicillin are given. Antifungals are used for chronic mucocutaneous candidiasis.
Immunosuppressive treatment such as cyclosporine and corticosteroids is given for pure red cell aplasia. Standard treatment such as acetylcholinesterase inhibitors and immunosuppressants is given for myasthenia gravis.
Because immunodeficiency mostly persists even after thymoma resection, long-term IVIG replacement therapy is needed. Complications from recurrent infections, bronchiectasis and opportunistic infections are the main causes of morbidity and mortality. The course of associated pure red cell aplasia or myasthenia gravis also affects prognosis.
The prognosis of thymoma itself varies with stage and histological type. Completely resected early-stage (Masaoka stage I, II) thymoma has a 5-year survival rate of over 90%.
Infection-related deaths can be reduced with appropriate IVIG treatment and prophylactic antibiotics. Lung function impairment (bronchiectasis, fibrosis) is a major factor determining long-term prognosis.
Thymoma is often asymptomatic and is frequently found incidentally on chest CT. When a thymoma is identified, immune function evaluation is performed immediately to begin early detection and treatment of Good syndrome.
Inactivated vaccines (pneumococcal, meningococcal, Hib, influenza, etc.) are actively given. Live vaccines are contraindicated in patients with immunodeficiency.
Thorough hand hygiene, avoidance of exposure to sources of infection, and prompt access to medical care when infection is suspected are recommended. Infections are treated early and aggressively to minimize lung damage from recurrent infections.